Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

ABSTRACT:

Background

Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socioeconomic. Evidence on the socioeconomic implications of CGRP-mAbs is, however, limited. There is an increasing interest in supplementing evidence from randomised controlled trials (RCTs) with real-world evidence (RWE) to aid clinical decision making and inform decision making for migraine management. The objective of this study was to generate RWE on the health economic and socioeconomic implications of administering CGRP-mAbs to patients with chronic migraine (CM) and episodic migraine

SUBMITTER: Siersbæk N 

PROVIDER: S-EPMC10316628 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature